Document is current

Article History

Received: 10 January 2019

Accepted: 27 February 2019

First Online: 21 March 2019

Ethics approval and consent to participate

: The ALFA study and the PET sub-study protocols have been approved by an independent Ethics Committee Parc de Salut Mar Barcelona and registered at Clinicaltrials.gov (ALFA Identifier: NCT02485730; PET sub-study Identifier: NCT02685969). Both studies have been conducted in accordance with the directives of the Spanish Law 14/ 2007, of 3rd of July, on Biomedical Research (Ley 14/ 2007 de Investigación Biomédica).

: Not applicable.

: JLM is a consultant for the following for-profit companies: Alergan, Roche diagnostics, Genentech, Novartis, Lundbeck, Oryzon, Biogen, Lilly, Janssen, Green Valley, MSD, Eisai, Alector, Raman Health.Other authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.